Abstract: Myeloid derived suppressor cells(MDSCs) is a kind of significant heterogeneous cells of the immunosuppressive activity, including at different developmental stages of immature granulocytes, dendritic cells and macrophages, and so on. Myeloid derived suppressor cells can inhibit the innate immunity, adaptive immunity mediated by CD4+ and CD8+ T cells, and stimulate tumor growth and metastasis through mediated tumor immune escape. Proinflammatory cytokines are a group of endogenous polypeptides that are mainly produced by immune system cells and have powerful biological effects. They mediate a variety of immune responses. Although molecular mechanisms of MDSCs and proinflammatory cytokines in ovarian cancer are not quite clear, but the current study suggests that some proinflammatory cytokines can induce MDSCs amplification, thus promoting tumor growth and development. Targeted therapies are new treatments besides routine surgery and chemotherapy. MDSCs have potential as clinical targets for immunotherapy. This article reviews research on the occurrence, development and treatment of MDSCs in ovarian carcinoma in order to reveal the mechanism of action of MDSCs and the provide theoretical basis for new treatment methods.

Key words: Interleukins, Prostaglandins E, Vascular endothelial growth factors, Ovarian neoplasms, Immune tolerance, Immunotherapy, MDSCs